Jan 29, 2026
Healthcare
Mapping Rare Disease in 2026
White Papers
Stifel IRIS is delighted to announce the release of “Mapping Rare Disease in 2026: Cumulative Progress, Structural Gaps, and the Road Ahead”, an in-depth analysis of the evolving orphan drug landscape and the emerging strategic opportunities within the European biotechnology sector.
What this paper covers:
The rare disease sector has transformed from isolated research into a unified industry, yet treatments exist for less than 10% of the 6,000 to 8,000 recognised conditions, despite affecting 300 million people worldwide. Although nearly half of new clinical trials now focus on rare diseases, the field still faces significant hurdles in delivering therapies, pricing them sustainably, and manufacturing at scale. Advances in genomic sequencing are making disease classification more precise, setting a new standard for clinical success based on overcoming complex biological delivery challenges.
Our latest white paper, “Mapping Rare Disease in 2026,” presents a strategic overview of a sector where progress is increasingly defined by repeatable platforms and standardized development models, supported by Europe’s maturing industrial base.
The paper closes on a look forward, expecting the next ten decades to deliver transformative advancements in gene therapy and blood-brain barrier penetration. For a deeper look at these trends and a detailed map of over 150 European rare disease biotech firms, download the full report.
Written by Clemence Thiers
